BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation®, a global leader in minimally invasive brachytherapy, interventional devices, surgical products, and medical device design services, today announced the appointment of Mark Pugh as its new CEO, effective immediately. Mr. Pugh succeeds Frank Tarallo, who retired at the end of 2023 after a decade of distinguished leadership at the helm of Theragenics..

佐治亚州布福德——（商业新闻短讯）——微创近距离放射治疗、介入设备、外科产品和医疗器械设计服务领域的全球领导者Theragenics Corporation®今天宣布任命Mark Pugh为其新任CEO，立即生效。普格先生接替弗兰克·塔拉洛（FrankTarallo），后者在领导治疗机构十年后于2023年底退休。。

Mr. Pugh brings over 20 years of medical device industry expertise to his new role and boasts a proven track record of driving strategic expansion and growth. His most recent role at Theragenics was as President of the OEM Group, where he oversaw the company's design and contract manufacturing services and its subsidiaries – Arrotek Medical, Galt Medical, and NeedleTech.

普格先生将20多年的医疗器械行业专业知识带到了他的新职位上，并拥有推动战略扩张和增长的良好记录。他最近在Theragenics担任OEM集团总裁，负责监督该公司的设计和合同制造服务及其子公司——Arrotek Medical、Galt Medical和NeedleTech。

Notably, Mr. Pugh co-founded Arrotek Medical, an industry-leading medical device design consultancy specializing in minimally invasive devices. Under his leadership, Arrotek grew from a two-person startup in Sligo, Ireland to a thriving global enterprise with over 100 employees and has assisted over 250 companies to develop their own medical devices.

值得注意的是，Pugh先生与人共同创立了Arrotek Medical，这是一家行业领先的医疗器械设计咨询公司，专门从事微创器械。在他的领导下，Arrotek从爱尔兰斯莱戈的一家两人创业公司成长为一家拥有100多名员工的蓬勃发展的全球企业，并帮助250多家公司开发了自己的医疗设备。

Arrotek Medical was acquired by Theragenics in 2019..

Arrotek Medical于2019年被Theragenics收购。。

'I am deeply passionate about Theragenics' mission of delivering life-changing minimally invasive medical solutions,' stated Mr. Pugh. 'This company possesses a robust foundation, innovative products, and a diversified portfolio of capabilities across multiple growing therapeutic areas. I am thrilled to collaborate with our exceptional leadership team and board of directors to propel Theragenics to new heights, cultivate a culture of innovation, optimize operational efficiencies, and ultimately enhance the value we deliver to our customers, clinicians, and most importantly, the patients we serve.'.

普格说，我对治疗学提供改变生活的微创医疗解决方案的使命充满热情该公司拥有强大的基础、创新的产品以及跨越多个不断增长的治疗领域的多元化能力组合。我很高兴与我们杰出的领导团队和董事会合作，推动治疗技术达到新的高度，培养创新文化，优化运营效率，并最终提高我们为客户，临床医生，最重要的是我们服务的患者提供的价值。”。

About Theragenics Corporation

关于Theragenics Corporation

Theragenics delivers innovative life-changing medical solutions that help shape better futures for patients. Pioneers in the field of brachytherapy, we offer minimally invasive, radiation-based treatments for prostate and other cancers, trusted by clinicians worldwide. Through our subsidiaries (www.arrotek.com, www.galtmedical.com), we design and deliver a diverse portfolio of vascular access, specialty needles products, and surgical devices, serving critical needs across interventional radiology, interventional cardiology, and vascular surgery.

Theragenics提供创新的改变生活的医疗解决方案，帮助患者塑造更好的未来。作为近距离放射治疗领域的先驱，我们为前列腺癌和其他癌症提供微创放射治疗，受到全球临床医生的信任。通过我们的子公司（www.arrotek.com，www.galtmedical.com），我们设计并提供了多种血管通路、专用针头产品和手术设备，满足介入放射学、介入心脏病学和血管外科的关键需求。

For additional information, please visit www.theragenics.com..

有关更多信息，请访问www.theragenics.com。。